Using Dose Titration to Resolve Diarrhea on Wegovy (semaglutide 2.4 mg)

What the Wegovy label lets you change about the dose

The Wegovy injection label escalates on a fixed 4-week clock: 0.25 mg for weeks 1 to 4, 0.5 mg for weeks 5 to 8, 1 mg for weeks 9 to 12, 1.7 mg for weeks 13 to 16, then a maintenance dose from week 17 [1]. It says to follow this schedule to minimize gastrointestinal adverse reactions and that, if a dose is not tolerated during escalation, delaying escalation for 4 weeks can be considered [1]. For weight reduction in adults the maintenance dose is 2.4 mg (recommended) or 1.7 mg; the same two doses apply to cardiovascular risk reduction, and for MASH the label gives 2.4 mg with a reduction to 1.7 mg allowed [1].

Going above 2.4 mg is a separate decision. The 7.2 mg weekly dose is for adults who tolerate 2.4 mg for at least 4 weeks and need more weight loss, and it is not a pediatric dose [1].

The label also ties dose to interruptions. A missed weekly dose is given if the next scheduled dose is more than 2 days away, and after 2 or more consecutive missed doses the label says to re-escalate from a lower dose [1].

Does each dose step make diarrhea more likely?

In pooled trials of Wegovy 2.4 mg injection in adults with obesity or overweight, 30% reported diarrhea versus 16% on placebo [1]. The label reports this rate for the 2.4 mg group, not for each escalation step [1].

What slower titration is known to do

A 2025 review of GLP-1 obesity drugs notes that gastrointestinal effects, including diarrhea, often can be mitigated by slow up-titration, but it does not establish how long to remain at a dose [2]. The label's own provision is the optional 4-week delay in escalation described above, and its escalation step is 4 weeks at each dose [1].

What the label says to watch for while you adjust the dose

The label warns about acute kidney injury from volume depletion and says to monitor renal function in patients reporting adverse reactions that could lead to volume depletion [1]. In the Wegovy trials this occurred in 0.4 versus 0.2 cases per 100 patient-years (7 versus 4 adults), more often in people with existing kidney impairment and during dose titration, often after gastrointestinal fluid loss [1].

Severe gastrointestinal adverse reactions were reported by 4.1% of adults on Wegovy injection versus 0.9% on placebo, and Wegovy is not recommended in patients with severe gastroparesis [1]. Postmarketing reports in the Wegovy label include ileus, intestinal obstruction and severe constipation with fecal impaction [1]. For persistent or severe abdominal pain, the pancreatitis warning says to discontinue Wegovy and start appropriate management if pancreatitis is suspected [1].